Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.

ABSTRACT:

Background

Mantle cell lymphoma (MCL) remains incurable using conventional chemotherapeutic approaches. New clinical data show that some patients have a chronic/indolent course and others have a more fulminant course and short survival, similar to that of patients with acute leukemias.

Methods

This review presents an overview of this aggressive disease, including the diagnosis, epidemiology, prognosis, and management of this protean and challenging condition.

Results

Distinguishing indolent MCL from in situ MCL is important but can be challenging. Molecular exploration has identified SOX11 and HDAC11 as potential candidate genes for discrimination of indolent cases. Improvements in the prognosis in MCL are likely the result of earlier identification of more indolent c

SUBMITTER: Shah BD 

PROVIDER: S-EPMC4015063 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature